| Literature DB >> 25674858 |
William Makis1, Karey McCann, Alexander J B McEwan.
Abstract
Two patients diagnosed with metastatic medullary thyroid carcinoma (MTC) were referred for peptide receptor radionuclide therapy (PRRT) with Lu-[DOTA,Tyr]octreotate (DOTATATE). Each patient was treated with 4 doses of Lu-DOTATATE given 2 months apart. One patient achieved stable disease for 10 months then chose to pursue surgery, and the other achieved stable disease for 9 months on imaging; however, calcitonin continued to rise. The use of Lu-DOTATATE PRRT therapy in the management of MTC warrants further research.Entities:
Mesh：
Substances：
Year: 2015 PMID： 25674858 DOI： 10.1097/RLU.0000000000000706
Source DB: PubMed Journal: Clin Nucl Med ISSN： 0363-9762 Impact factor: 7.794